Dr. Mohamed Kamel Mohamed, MD

Dr. Mohamed practices at Cone , Annie Penn, Randolph Cancer Centers - HOPD in Greensboro, North Carolina.

Dr. Mohamed's NPI, 1346293784, was assigned on May 18, 2006. Dr. Mohamed holds North Carolina license 200500089.

Dr. Mohamed's primary practice is Cone , Annie Penn, Randolph Cancer Centers - HOPD, at 501 North Elam Avenue, Greensboro, NC 27403.

Dr. Mohamed's primary practice is Cone , Annie Penn, Randolph Cancer Centers - HOPD in Greensboro, North Carolina. Dr. Mohamed is also affiliated with Cone Health Moses Cone Hospital. The medical group on file is Cone Health. Dmand AI also links Dr. Mohamed to 1 more group practice or clinic, named with a free account. Dr. Mohamed's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mohamed practices, 3 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Mohamed's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Mohamed is licensed in North Carolina.

CMS data shows 953 Medicare services from Dr. Mohamed across 7 procedure codes in 2024, for 314 Medicare patients. Medicare paid $56,645 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 314 Medicare patients who saw Dr. Mohamed in 2024. The largest group is 65 to 74, with 137 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 2.25, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mohamed's median patient age at 72, with 54% women.

In 2024, Dr. Mohamed wrote 1,284 Medicare Part D claims for 269 patients. 74% of them were for generic drugs. CMS names the drug for 1,039 of them, across 29 drugs with 11 or more claims each, at $3,691,933 in total drug cost. In 2023, CMS named 736 claims across 28 drugs.

Dr. Mohamed accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 4 papers to Dr. Mohamed, published from 2015 to 2018. Dr. Mohamed's most frequent co-authors are David M. Waterhouse, MD, Kenneth Bruce Blankstein, MD and Rodolfo Eduardo Bordoni, MD.

Dmand AI links Dr. Mohamed to 2 clinical trials. Conditions studied include Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung and Small Cell Lung Carcinoma.

CMS Open Payments shows 1,636 general payments to Dr. Mohamed from 34 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 66% of the total. AstraZeneca Pharmaceuticals LP paid the most, $379,116.